LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Fechado

SetorSaúde

19.47 -3.04

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.19

Máximo

19.54

Indicadores-chave
By Trading Economics
Rendimento	102K -128M
EPS	-0.69
Funcionários	507
EBITDA	-9.8M -135M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+76.27% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	277M 3.2B
Abertura anterior	22.51
Fecho anterior	19.47

Sentimento de Notícias

By Acuity

67%

33%

290 / 344 Ranking em Healthcare

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2026, 19:20 UTC

Grandes Movimentos do Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 de jun. de 2026, 21:27 UTC

Ganhos

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 20:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 de jun. de 2026, 20:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 de jun. de 2026, 19:10 UTC

Conversa de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 de jun. de 2026, 19:03 UTC

Conversa de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 de jun. de 2026, 18:59 UTC

Conversa de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 de jun. de 2026, 18:47 UTC

Conversa de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 de jun. de 2026, 18:34 UTC

Conversa de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 de jun. de 2026, 18:33 UTC

Aquisições, Fusões, Aquisições de Empresas

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 de jun. de 2026, 17:50 UTC

Ganhos

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 de jun. de 2026, 17:27 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 de jun. de 2026, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

5 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2026, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 de jun. de 2026, 15:26 UTC

Conversa de Mercado

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 de jun. de 2026, 15:25 UTC

Ganhos

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 de jun. de 2026, 15:16 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de jun. de 2026, 15:16 UTC

Conversa de Mercado

Zcash Tumbles After Exploit Found -- Market Talk

5 de jun. de 2026, 15:09 UTC

Conversa de Mercado

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 de jun. de 2026, 15:07 UTC

Conversa de Mercado

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 de jun. de 2026, 15:05 UTC

Conversa de Mercado

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

76.27% parte superior

Previsão para 12 meses

Média 35.5 USD 76.27%

Máximo 42 USD

Mínimo 23 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

290 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.